Sen. Kyle McCarter

Filed: 4/15/2015

 

 


 

 


 
09900SB1282sam001LRB099 03815 RLC 33711 a

1
AMENDMENT TO SENATE BILL 1282

2    AMENDMENT NO. ______. Amend Senate Bill 1282 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 102, 204, 401, and 402 as follows:
 
6    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
7    Sec. 102. Definitions. As used in this Act, unless the
8context otherwise requires:
9    (a) "Addict" means any person who habitually uses any drug,
10chemical, substance or dangerous drug other than alcohol so as
11to endanger the public morals, health, safety or welfare or who
12is so far addicted to the use of a dangerous drug or controlled
13substance other than alcohol as to have lost the power of self
14control with reference to his or her addiction.
15    (b) "Administer" means the direct application of a
16controlled substance, whether by injection, inhalation,

 

 

09900SB1282sam001- 2 -LRB099 03815 RLC 33711 a

1ingestion, or any other means, to the body of a patient,
2research subject, or animal (as defined by the Humane
3Euthanasia in Animal Shelters Act) by:
4        (1) a practitioner (or, in his or her presence, by his
5    or her authorized agent),
6        (2) the patient or research subject pursuant to an
7    order, or
8        (3) a euthanasia technician as defined by the Humane
9    Euthanasia in Animal Shelters Act.
10    (c) "Agent" means an authorized person who acts on behalf
11of or at the direction of a manufacturer, distributor,
12dispenser, prescriber, or practitioner. It does not include a
13common or contract carrier, public warehouseman or employee of
14the carrier or warehouseman.
15    (c-1) "Anabolic Steroids" means any drug or hormonal
16substance, chemically and pharmacologically related to
17testosterone (other than estrogens, progestins,
18corticosteroids, and dehydroepiandrosterone), and includes:
19    (i) 3[beta],17-dihydroxy-5a-androstane, 
20    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
21    (iii) 5[alpha]-androstan-3,17-dione, 
22    (iv) 1-androstenediol (3[beta], 
23        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
24    (v) 1-androstenediol (3[alpha], 
25        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
26    (vi) 4-androstenediol  

 

 

09900SB1282sam001- 3 -LRB099 03815 RLC 33711 a

1        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
2    (vii) 5-androstenediol  
3        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
4    (viii) 1-androstenedione  
5        ([5alpha]-androst-1-en-3,17-dione), 
6    (ix) 4-androstenedione  
7        (androst-4-en-3,17-dione), 
8    (x) 5-androstenedione  
9        (androst-5-en-3,17-dione), 
10    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
11        hydroxyandrost-4-en-3-one), 
12    (xii) boldenone (17[beta]-hydroxyandrost- 
13        1,4,-diene-3-one), 
14    (xiii) boldione (androsta-1,4- 
15        diene-3,17-dione), 
16    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
17        [beta]-hydroxyandrost-4-en-3-one), 
18    (xv) clostebol (4-chloro-17[beta]- 
19        hydroxyandrost-4-en-3-one), 
20    (xvi) dehydrochloromethyltestosterone (4-chloro- 
21        17[beta]-hydroxy-17[alpha]-methyl- 
22        androst-1,4-dien-3-one), 
23    (xvii) desoxymethyltestosterone 
24    (17[alpha]-methyl-5[alpha] 
25        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
26    (xviii) [delta]1-dihydrotestosterone (a.k.a.  

 

 

09900SB1282sam001- 4 -LRB099 03815 RLC 33711 a

1        '1-testosterone') (17[beta]-hydroxy- 
2        5[alpha]-androst-1-en-3-one), 
3    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
4        androstan-3-one), 
5    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
6        5[alpha]-androstan-3-one), 
7    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
8        hydroxyestr-4-ene), 
9    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
10        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
11    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
12        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
13    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
14        hydroxyandrostano[2,3-c]-furazan), 
15    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
16    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
17        androst-4-en-3-one), 
18    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
19        dihydroxy-estr-4-en-3-one), 
20    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
21        hydroxy-5-androstan-3-one), 
22    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
23        [5a]-androstan-3-one), 
24    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
25        hydroxyandrost-1,4-dien-3-one), 
26    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 

 

 

09900SB1282sam001- 5 -LRB099 03815 RLC 33711 a

1        dihydroxyandrost-5-ene), 
2    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
3        5[alpha]-androst-1-en-3-one), 
4    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
5        dihydroxy-5a-androstane), 
6    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
7        -5a-androstane), 
8    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
9        dihydroxyandrost-4-ene), 
10    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
11        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
12    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
13        hydroxyestra-4,9(10)-dien-3-one), 
14    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
15        hydroxyestra-4,9-11-trien-3-one), 
16    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
17        hydroxyandrost-4-en-3-one), 
18    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
19        hydroxyestr-4-en-3-one), 
20    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
21        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
22        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
23        1-testosterone'), 
24    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
25    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
26        dihydroxyestr-4-ene), 

 

 

09900SB1282sam001- 6 -LRB099 03815 RLC 33711 a

1    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
2        dihydroxyestr-4-ene), 
3    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
4        dihydroxyestr-5-ene), 
5    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
6        dihydroxyestr-5-ene), 
7    (xlvii) 19-nor-4,9(10)-androstadienedione  
8        (estra-4,9(10)-diene-3,17-dione), 
9    (xlviii) 19-nor-4-androstenedione (estr-4- 
10        en-3,17-dione), 
11    (xlix) 19-nor-5-androstenedione (estr-5- 
12        en-3,17-dione), 
13    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
14        hydroxygon-4-en-3-one), 
15    (li) norclostebol (4-chloro-17[beta]- 
16        hydroxyestr-4-en-3-one), 
17    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
18        hydroxyestr-4-en-3-one), 
19    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
20        hydroxyestr-4-en-3-one), 
21    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
22        2-oxa-5[alpha]-androstan-3-one), 
23    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
24        dihydroxyandrost-4-en-3-one), 
25    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
26        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 

 

 

09900SB1282sam001- 7 -LRB099 03815 RLC 33711 a

1    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
2        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
3    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
4        (5[alpha]-androst-1-en-3-one), 
5    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
6        secoandrosta-1,4-dien-17-oic 
7        acid lactone), 
8    (lx) testosterone (17[beta]-hydroxyandrost- 
9        4-en-3-one), 
10    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
11        diethyl-17[beta]-hydroxygon- 
12        4,9,11-trien-3-one), 
13    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
14        11-trien-3-one). 
15    Any person who is otherwise lawfully in possession of an
16anabolic steroid, or who otherwise lawfully manufactures,
17distributes, dispenses, delivers, or possesses with intent to
18deliver an anabolic steroid, which anabolic steroid is
19expressly intended for and lawfully allowed to be administered
20through implants to livestock or other nonhuman species, and
21which is approved by the Secretary of Health and Human Services
22for such administration, and which the person intends to
23administer or have administered through such implants, shall
24not be considered to be in unauthorized possession or to
25unlawfully manufacture, distribute, dispense, deliver, or
26possess with intent to deliver such anabolic steroid for

 

 

09900SB1282sam001- 8 -LRB099 03815 RLC 33711 a

1purposes of this Act.
2    (d) "Administration" means the Drug Enforcement
3Administration, United States Department of Justice, or its
4successor agency.
5    (d-5) "Clinical Director, Prescription Monitoring Program"
6means a Department of Human Services administrative employee
7licensed to either prescribe or dispense controlled substances
8who shall run the clinical aspects of the Department of Human
9Services Prescription Monitoring Program and its Prescription
10Information Library.
11    (d-10) "Compounding" means the preparation and mixing of
12components, excluding flavorings, (1) as the result of a
13prescriber's prescription drug order or initiative based on the
14prescriber-patient-pharmacist relationship in the course of
15professional practice or (2) for the purpose of, or incident
16to, research, teaching, or chemical analysis and not for sale
17or dispensing. "Compounding" includes the preparation of drugs
18or devices in anticipation of receiving prescription drug
19orders based on routine, regularly observed dispensing
20patterns. Commercially available products may be compounded
21for dispensing to individual patients only if both of the
22following conditions are met: (i) the commercial product is not
23reasonably available from normal distribution channels in a
24timely manner to meet the patient's needs and (ii) the
25prescribing practitioner has requested that the drug be
26compounded.

 

 

09900SB1282sam001- 9 -LRB099 03815 RLC 33711 a

1    (e) "Control" means to add a drug or other substance, or
2immediate precursor, to a Schedule whether by transfer from
3another Schedule or otherwise.
4    (f) "Controlled Substance" means (i) a drug, substance, or
5immediate precursor, or synthetic drug in the Schedules of
6Article II of this Act or (ii) a drug or other substance, or
7immediate precursor, designated as a controlled substance by
8the Department through administrative rule. The term does not
9include distilled spirits, wine, malt beverages, or tobacco, as
10those terms are defined or used in the Liquor Control Act of
111934 and the Tobacco Products Tax Act of 1995.
12    (f-5) "Controlled substance analog" means a substance:
13        (1) the chemical structure of which is substantially
14    similar to the chemical structure of a controlled substance
15    in Schedule I or II;
16        (2) which has a stimulant, depressant, or
17    hallucinogenic effect on the central nervous system that is
18    substantially similar to or greater than the stimulant,
19    depressant, or hallucinogenic effect on the central
20    nervous system of a controlled substance in Schedule I or
21    II; or
22        (3) with respect to a particular person, which such
23    person represents or intends to have a stimulant,
24    depressant, or hallucinogenic effect on the central
25    nervous system that is substantially similar to or greater
26    than the stimulant, depressant, or hallucinogenic effect

 

 

09900SB1282sam001- 10 -LRB099 03815 RLC 33711 a

1    on the central nervous system of a controlled substance in
2    Schedule I or II.
3    (g) "Counterfeit substance" means a controlled substance,
4which, or the container or labeling of which, without
5authorization bears the trademark, trade name, or other
6identifying mark, imprint, number or device, or any likeness
7thereof, of a manufacturer, distributor, or dispenser other
8than the person who in fact manufactured, distributed, or
9dispensed the substance.
10    (h) "Deliver" or "delivery" means the actual, constructive
11or attempted transfer of possession of a controlled substance,
12with or without consideration, whether or not there is an
13agency relationship.
14    (i) "Department" means the Illinois Department of Human
15Services (as successor to the Department of Alcoholism and
16Substance Abuse) or its successor agency.
17    (j) (Blank).
18    (k) "Department of Corrections" means the Department of
19Corrections of the State of Illinois or its successor agency.
20    (l) "Department of Financial and Professional Regulation"
21means the Department of Financial and Professional Regulation
22of the State of Illinois or its successor agency.
23    (m) "Depressant" means any drug that (i) causes an overall
24depression of central nervous system functions, (ii) causes
25impaired consciousness and awareness, and (iii) can be
26habit-forming or lead to a substance abuse problem, including

 

 

09900SB1282sam001- 11 -LRB099 03815 RLC 33711 a

1but not limited to alcohol, cannabis and its active principles
2and their analogs, benzodiazepines and their analogs,
3barbiturates and their analogs, opioids (natural and
4synthetic) and their analogs, and chloral hydrate and similar
5sedative hypnotics.
6    (n) (Blank).
7    (o) "Director" means the Director of the Illinois State
8Police or his or her designated agents.
9    (p) "Dispense" means to deliver a controlled substance to
10an ultimate user or research subject by or pursuant to the
11lawful order of a prescriber, including the prescribing,
12administering, packaging, labeling, or compounding necessary
13to prepare the substance for that delivery.
14    (q) "Dispenser" means a practitioner who dispenses.
15    (r) "Distribute" means to deliver, other than by
16administering or dispensing, a controlled substance.
17    (s) "Distributor" means a person who distributes.
18    (t) "Drug" means (1) substances recognized as drugs in the
19official United States Pharmacopoeia, Official Homeopathic
20Pharmacopoeia of the United States, or official National
21Formulary, or any supplement to any of them; (2) substances
22intended for use in diagnosis, cure, mitigation, treatment, or
23prevention of disease in man or animals; (3) substances (other
24than food) intended to affect the structure of any function of
25the body of man or animals and (4) substances intended for use
26as a component of any article specified in clause (1), (2), or

 

 

09900SB1282sam001- 12 -LRB099 03815 RLC 33711 a

1(3) of this subsection. It does not include devices or their
2components, parts, or accessories.
3    (t-5) "Euthanasia agency" means an entity certified by the
4Department of Financial and Professional Regulation for the
5purpose of animal euthanasia that holds an animal control
6facility license or animal shelter license under the Animal
7Welfare Act. A euthanasia agency is authorized to purchase,
8store, possess, and utilize Schedule II nonnarcotic and
9Schedule III nonnarcotic drugs for the sole purpose of animal
10euthanasia.
11    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
12substances (nonnarcotic controlled substances) that are used
13by a euthanasia agency for the purpose of animal euthanasia.
14    (u) "Good faith" means the prescribing or dispensing of a
15controlled substance by a practitioner in the regular course of
16professional treatment to or for any person who is under his or
17her treatment for a pathology or condition other than that
18individual's physical or psychological dependence upon or
19addiction to a controlled substance, except as provided herein:
20and application of the term to a pharmacist shall mean the
21dispensing of a controlled substance pursuant to the
22prescriber's order which in the professional judgment of the
23pharmacist is lawful. The pharmacist shall be guided by
24accepted professional standards including, but not limited to
25the following, in making the judgment:
26        (1) lack of consistency of prescriber-patient

 

 

09900SB1282sam001- 13 -LRB099 03815 RLC 33711 a

1    relationship,
2        (2) frequency of prescriptions for same drug by one
3    prescriber for large numbers of patients,
4        (3) quantities beyond those normally prescribed,
5        (4) unusual dosages (recognizing that there may be
6    clinical circumstances where more or less than the usual
7    dose may be used legitimately),
8        (5) unusual geographic distances between patient,
9    pharmacist and prescriber,
10        (6) consistent prescribing of habit-forming drugs.
11    (u-0.5) "Hallucinogen" means a drug that causes markedly
12altered sensory perception leading to hallucinations of any
13type.
14    (u-1) "Home infusion services" means services provided by a
15pharmacy in compounding solutions for direct administration to
16a patient in a private residence, long-term care facility, or
17hospice setting by means of parenteral, intravenous,
18intramuscular, subcutaneous, or intraspinal infusion.
19    (u-5) "Illinois State Police" means the State Police of the
20State of Illinois, or its successor agency.
21    (v) "Immediate precursor" means a substance:
22        (1) which the Department has found to be and by rule
23    designated as being a principal compound used, or produced
24    primarily for use, in the manufacture of a controlled
25    substance;
26        (2) which is an immediate chemical intermediary used or

 

 

09900SB1282sam001- 14 -LRB099 03815 RLC 33711 a

1    likely to be used in the manufacture of such controlled
2    substance; and
3        (3) the control of which is necessary to prevent,
4    curtail or limit the manufacture of such controlled
5    substance.
6    (w) "Instructional activities" means the acts of teaching,
7educating or instructing by practitioners using controlled
8substances within educational facilities approved by the State
9Board of Education or its successor agency.
10    (x) "Local authorities" means a duly organized State,
11County or Municipal peace unit or police force.
12    (y) "Look-alike substance" means a substance, other than a
13controlled substance which (1) by overall dosage unit
14appearance, including shape, color, size, markings or lack
15thereof, taste, consistency, or any other identifying physical
16characteristic of the substance, would lead a reasonable person
17to believe that the substance is a controlled substance, or (2)
18is expressly or impliedly represented to be a controlled
19substance or is distributed under circumstances which would
20lead a reasonable person to believe that the substance is a
21controlled substance. For the purpose of determining whether
22the representations made or the circumstances of the
23distribution would lead a reasonable person to believe the
24substance to be a controlled substance under this clause (2) of
25subsection (y), the court or other authority may consider the
26following factors in addition to any other factor that may be

 

 

09900SB1282sam001- 15 -LRB099 03815 RLC 33711 a

1relevant:
2        (a) statements made by the owner or person in control
3    of the substance concerning its nature, use or effect;
4        (b) statements made to the buyer or recipient that the
5    substance may be resold for profit;
6        (c) whether the substance is packaged in a manner
7    normally used for the illegal distribution of controlled
8    substances;
9        (d) whether the distribution or attempted distribution
10    included an exchange of or demand for money or other
11    property as consideration, and whether the amount of the
12    consideration was substantially greater than the
13    reasonable retail market value of the substance.
14    Clause (1) of this subsection (y) shall not apply to a
15noncontrolled substance in its finished dosage form that was
16initially introduced into commerce prior to the initial
17introduction into commerce of a controlled substance in its
18finished dosage form which it may substantially resemble.
19    Nothing in this subsection (y) prohibits the dispensing or
20distributing of noncontrolled substances by persons authorized
21to dispense and distribute controlled substances under this
22Act, provided that such action would be deemed to be carried
23out in good faith under subsection (u) if the substances
24involved were controlled substances.
25    Nothing in this subsection (y) or in this Act prohibits the
26manufacture, preparation, propagation, compounding,

 

 

09900SB1282sam001- 16 -LRB099 03815 RLC 33711 a

1processing, packaging, advertising or distribution of a drug or
2drugs by any person registered pursuant to Section 510 of the
3Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
4    (y-1) "Mail-order pharmacy" means a pharmacy that is
5located in a state of the United States that delivers,
6dispenses or distributes, through the United States Postal
7Service or other common carrier, to Illinois residents, any
8substance which requires a prescription.
9    (z) "Manufacture" means the production, preparation,
10propagation, compounding, conversion or processing of a
11controlled substance other than methamphetamine, either
12directly or indirectly, by extraction from substances of
13natural origin, or independently by means of chemical
14synthesis, or by a combination of extraction and chemical
15synthesis, and includes any packaging or repackaging of the
16substance or labeling of its container, except that this term
17does not include:
18        (1) by an ultimate user, the preparation or compounding
19    of a controlled substance for his or her own use; or
20        (2) by a practitioner, or his or her authorized agent
21    under his or her supervision, the preparation,
22    compounding, packaging, or labeling of a controlled
23    substance:
24            (a) as an incident to his or her administering or
25        dispensing of a controlled substance in the course of
26        his or her professional practice; or

 

 

09900SB1282sam001- 17 -LRB099 03815 RLC 33711 a

1            (b) as an incident to lawful research, teaching or
2        chemical analysis and not for sale.
3    (z-1) (Blank).
4    (z-5) "Medication shopping" means the conduct prohibited
5under subsection (a) of Section 314.5 of this Act.
6    (z-10) "Mid-level practitioner" means (i) a physician
7assistant who has been delegated authority to prescribe through
8a written delegation of authority by a physician licensed to
9practice medicine in all of its branches, in accordance with
10Section 7.5 of the Physician Assistant Practice Act of 1987,
11(ii) an advanced practice nurse who has been delegated
12authority to prescribe through a written delegation of
13authority by a physician licensed to practice medicine in all
14of its branches or by a podiatric physician, in accordance with
15Section 65-40 of the Nurse Practice Act, (iii) an animal
16euthanasia agency, or (iv) a prescribing psychologist.
17    (aa) "Narcotic drug" means any of the following, whether
18produced directly or indirectly by extraction from substances
19of vegetable origin, or independently by means of chemical
20synthesis, or by a combination of extraction and chemical
21synthesis:
22        (1) opium, opiates, derivatives of opium and opiates,
23    including their isomers, esters, ethers, salts, and salts
24    of isomers, esters, and ethers, whenever the existence of
25    such isomers, esters, ethers, and salts is possible within
26    the specific chemical designation; however the term

 

 

09900SB1282sam001- 18 -LRB099 03815 RLC 33711 a

1    "narcotic drug" does not include the isoquinoline
2    alkaloids of opium;
3        (2) (blank);
4        (3) opium poppy and poppy straw;
5        (4) coca leaves, except coca leaves and extracts of
6    coca leaves from which substantially all of the cocaine and
7    ecgonine, and their isomers, derivatives and salts, have
8    been removed;
9        (5) cocaine, its salts, optical and geometric isomers,
10    and salts of isomers;
11        (6) ecgonine, its derivatives, their salts, isomers,
12    and salts of isomers;
13        (7) any compound, mixture, or preparation which
14    contains any quantity of any of the substances referred to
15    in subparagraphs (1) through (6).
16    (bb) "Nurse" means a registered nurse licensed under the
17Nurse Practice Act.
18    (cc) (Blank).
19    (dd) "Opiate" means any substance having an addiction
20forming or addiction sustaining liability similar to morphine
21or being capable of conversion into a drug having addiction
22forming or addiction sustaining liability.
23    (ee) "Opium poppy" means the plant of the species Papaver
24somniferum L., except its seeds.
25    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
26solution or other liquid form of medication intended for

 

 

09900SB1282sam001- 19 -LRB099 03815 RLC 33711 a

1administration by mouth, but the term does not include a form
2of medication intended for buccal, sublingual, or transmucosal
3administration.
4    (ff) "Parole and Pardon Board" means the Parole and Pardon
5Board of the State of Illinois or its successor agency.
6    (gg) "Person" means any individual, corporation,
7mail-order pharmacy, government or governmental subdivision or
8agency, business trust, estate, trust, partnership or
9association, or any other entity.
10    (hh) "Pharmacist" means any person who holds a license or
11certificate of registration as a registered pharmacist, a local
12registered pharmacist or a registered assistant pharmacist
13under the Pharmacy Practice Act.
14    (ii) "Pharmacy" means any store, ship or other place in
15which pharmacy is authorized to be practiced under the Pharmacy
16Practice Act.
17    (ii-5) "Pharmacy shopping" means the conduct prohibited
18under subsection (b) of Section 314.5 of this Act.
19    (ii-10) "Physician" (except when the context otherwise
20requires) means a person licensed to practice medicine in all
21of its branches.
22    (jj) "Poppy straw" means all parts, except the seeds, of
23the opium poppy, after mowing.
24    (kk) "Practitioner" means a physician licensed to practice
25medicine in all its branches, dentist, optometrist, podiatric
26physician, veterinarian, scientific investigator, pharmacist,

 

 

09900SB1282sam001- 20 -LRB099 03815 RLC 33711 a

1physician assistant, advanced practice nurse, licensed
2practical nurse, registered nurse, hospital, laboratory, or
3pharmacy, or other person licensed, registered, or otherwise
4lawfully permitted by the United States or this State to
5distribute, dispense, conduct research with respect to,
6administer or use in teaching or chemical analysis, a
7controlled substance in the course of professional practice or
8research.
9    (ll) "Pre-printed prescription" means a written
10prescription upon which the designated drug has been indicated
11prior to the time of issuance; the term does not mean a written
12prescription that is individually generated by machine or
13computer in the prescriber's office.
14    (mm) "Prescriber" means a physician licensed to practice
15medicine in all its branches, dentist, optometrist,
16prescribing psychologist licensed under Section 4.2 of the
17Clinical Psychologist Licensing Act with prescriptive
18authority delegated under Section 4.3 of the Clinical
19Psychologist Licensing Act, podiatric physician, or
20veterinarian who issues a prescription, a physician assistant
21who issues a prescription for a controlled substance in
22accordance with Section 303.05, a written delegation, and a
23written supervision agreement required under Section 7.5 of the
24Physician Assistant Practice Act of 1987, or an advanced
25practice nurse with prescriptive authority delegated under
26Section 65-40 of the Nurse Practice Act and in accordance with

 

 

09900SB1282sam001- 21 -LRB099 03815 RLC 33711 a

1Section 303.05, a written delegation, and a written
2collaborative agreement under Section 65-35 of the Nurse
3Practice Act.
4    (nn) "Prescription" means a written, facsimile, or oral
5order, or an electronic order that complies with applicable
6federal requirements, of a physician licensed to practice
7medicine in all its branches, dentist, podiatric physician or
8veterinarian for any controlled substance, of an optometrist
9for a Schedule II, III, IV, or V controlled substance in
10accordance with Section 15.1 of the Illinois Optometric
11Practice Act of 1987, of a prescribing psychologist licensed
12under Section 4.2 of the Clinical Psychologist Licensing Act
13with prescriptive authority delegated under Section 4.3 of the
14Clinical Psychologist Licensing Act, of a physician assistant
15for a controlled substance in accordance with Section 303.05, a
16written delegation, and a written supervision agreement
17required under Section 7.5 of the Physician Assistant Practice
18Act of 1987, or of an advanced practice nurse with prescriptive
19authority delegated under Section 65-40 of the Nurse Practice
20Act who issues a prescription for a controlled substance in
21accordance with Section 303.05, a written delegation, and a
22written collaborative agreement under Section 65-35 of the
23Nurse Practice Act when required by law.
24    (nn-5) "Prescription Information Library" (PIL) means an
25electronic library that contains reported controlled substance
26data.

 

 

09900SB1282sam001- 22 -LRB099 03815 RLC 33711 a

1    (nn-10) "Prescription Monitoring Program" (PMP) means the
2entity that collects, tracks, and stores reported data on
3controlled substances and select drugs pursuant to Section 316.
4    (oo) "Production" or "produce" means manufacture,
5planting, cultivating, growing, or harvesting of a controlled
6substance other than methamphetamine.
7    (pp) "Registrant" means every person who is required to
8register under Section 302 of this Act.
9    (qq) "Registry number" means the number assigned to each
10person authorized to handle controlled substances under the
11laws of the United States and of this State.
12    (qq-5) "Secretary" means, as the context requires, either
13the Secretary of the Department or the Secretary of the
14Department of Financial and Professional Regulation, and the
15Secretary's designated agents.
16    (rr) "State" includes the State of Illinois and any state,
17district, commonwealth, territory, insular possession thereof,
18and any area subject to the legal authority of the United
19States of America.
20    (rr-5) "Stimulant" means any drug that (i) causes an
21overall excitation of central nervous system functions, (ii)
22causes impaired consciousness and awareness, and (iii) can be
23habit-forming or lead to a substance abuse problem, including
24but not limited to amphetamines and their analogs,
25methylphenidate and its analogs, cocaine, and phencyclidine
26and its analogs.

 

 

09900SB1282sam001- 23 -LRB099 03815 RLC 33711 a

1    (ss) "Ultimate user" means a person who lawfully possesses
2a controlled substance for his or her own use or for the use of
3a member of his or her household or for administering to an
4animal owned by him or her or by a member of his or her
5household.
6(Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; 98-668,
7eff. 6-25-14; 98-756, eff. 7-16-14; 98-1111, eff. 8-26-14;
8revised 10-1-14.)
 
9    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
10    Sec. 204. (a) The controlled substances listed in this
11Section are included in Schedule I.
12    (b) Unless specifically excepted or unless listed in
13another schedule, any of the following opiates, including their
14isomers, esters, ethers, salts, and salts of isomers, esters,
15and ethers, whenever the existence of such isomers, esters,
16ethers and salts is possible within the specific chemical
17designation:
18        (1) Acetylmethadol;
19        (1.1) Acetyl-alpha-methylfentanyl
20    (N-[1-(1-methyl-2-phenethyl)-
21    4-piperidinyl]-N-phenylacetamide);
22        (2) Allylprodine;
23        (3) Alphacetylmethadol, except
24    levo-alphacetylmethadol (also known as levo-alpha-
25    acetylmethadol, levomethadyl acetate, or LAAM);

 

 

09900SB1282sam001- 24 -LRB099 03815 RLC 33711 a

1        (4) Alphameprodine;
2        (5) Alphamethadol;
3        (6) Alpha-methylfentanyl
4    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
5    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
6    propanilido) piperidine;
7        (6.1) Alpha-methylthiofentanyl
8    (N-[1-methyl-2-(2-thienyl)ethyl-
9    4-piperidinyl]-N-phenylpropanamide);
10        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
11        (7.1) PEPAP
12    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
13        (8) Benzethidine;
14        (9) Betacetylmethadol;
15        (9.1) Beta-hydroxyfentanyl
16    (N-[1-(2-hydroxy-2-phenethyl)-
17    4-piperidinyl]-N-phenylpropanamide);
18        (10) Betameprodine;
19        (11) Betamethadol;
20        (12) Betaprodine;
21        (13) Clonitazene;
22        (14) Dextromoramide;
23        (15) Diampromide;
24        (16) Diethylthiambutene;
25        (17) Difenoxin;
26        (18) Dimenoxadol;

 

 

09900SB1282sam001- 25 -LRB099 03815 RLC 33711 a

1        (19) Dimepheptanol;
2        (20) Dimethylthiambutene;
3        (21) Dioxaphetylbutyrate;
4        (22) Dipipanone;
5        (23) Ethylmethylthiambutene;
6        (24) Etonitazene;
7        (25) Etoxeridine;
8        (26) Furethidine;
9        (27) Hydroxpethidine;
10        (28) Ketobemidone;
11        (29) Levomoramide;
12        (30) Levophenacylmorphan;
13        (31) 3-Methylfentanyl
14    (N-[3-methyl-1-(2-phenylethyl)-
15    4-piperidyl]-N-phenylpropanamide);
16        (31.1) 3-Methylthiofentanyl
17    (N-[(3-methyl-1-(2-thienyl)ethyl-
18    4-piperidinyl]-N-phenylpropanamide);
19        (32) Morpheridine;
20        (33) Noracymethadol;
21        (34) Norlevorphanol;
22        (35) Normethadone;
23        (36) Norpipanone;
24        (36.1) Para-fluorofentanyl
25    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
26    4-piperidinyl]propanamide);

 

 

09900SB1282sam001- 26 -LRB099 03815 RLC 33711 a

1        (37) Phenadoxone;
2        (38) Phenampromide;
3        (39) Phenomorphan;
4        (40) Phenoperidine;
5        (41) Piritramide;
6        (42) Proheptazine;
7        (43) Properidine;
8        (44) Propiram;
9        (45) Racemoramide;
10        (45.1) Thiofentanyl
11    (N-phenyl-N-[1-(2-thienyl)ethyl-
12    4-piperidinyl]-propanamide);
13        (46) Tilidine;
14        (47) Trimeperidine;
15        (48) Beta-hydroxy-3-methylfentanyl (other name:
16    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
17    N-phenylpropanamide).
18    (c) Unless specifically excepted or unless listed in
19another schedule, any of the following opium derivatives, its
20salts, isomers and salts of isomers, whenever the existence of
21such salts, isomers and salts of isomers is possible within the
22specific chemical designation:
23        (1) Acetorphine;
24        (2) Acetyldihydrocodeine;
25        (3) Benzylmorphine;
26        (4) Codeine methylbromide;

 

 

09900SB1282sam001- 27 -LRB099 03815 RLC 33711 a

1        (5) Codeine-N-Oxide;
2        (6) Cyprenorphine;
3        (7) Desomorphine;
4        (8) Diacetyldihydromorphine (Dihydroheroin);
5        (9) Dihydromorphine;
6        (10) Drotebanol;
7        (11) Etorphine (except hydrochloride salt);
8        (12) Heroin;
9        (13) Hydromorphinol;
10        (14) Methyldesorphine;
11        (15) Methyldihydromorphine;
12        (16) Morphine methylbromide;
13        (17) Morphine methylsulfonate;
14        (18) Morphine-N-Oxide;
15        (19) Myrophine;
16        (20) Nicocodeine;
17        (21) Nicomorphine;
18        (22) Normorphine;
19        (23) Pholcodine;
20        (24) Thebacon.
21    (d) Unless specifically excepted or unless listed in
22another schedule, any material, compound, mixture, or
23preparation which contains any quantity of the following
24hallucinogenic substances, or which contains any of its salts,
25isomers and salts of isomers, whenever the existence of such
26salts, isomers, and salts of isomers is possible within the

 

 

09900SB1282sam001- 28 -LRB099 03815 RLC 33711 a

1specific chemical designation (for the purposes of this
2paragraph only, the term "isomer" includes the optical,
3position and geometric isomers):
4        (1) 3,4-methylenedioxyamphetamine
5    (alpha-methyl,3,4-methylenedioxyphenethylamine,
6    methylenedioxyamphetamine, MDA);
7        (1.1) Alpha-ethyltryptamine
8    (some trade or other names: etryptamine;
9    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
10    3-(2-aminobutyl)indole; a-ET; and AET);
11        (2) 3,4-methylenedioxymethamphetamine (MDMA);
12        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
13    (also known as: N-ethyl-alpha-methyl-
14    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
15    and MDEA);
16        (2.2) N-Benzylpiperazine (BZP);
17        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
18        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
19        (4) 3,4,5-trimethoxyamphetamine (TMA);
20        (5) (Blank);
21        (6) Diethyltryptamine (DET);
22        (7) Dimethyltryptamine (DMT);
23        (7.1) 5-Methoxy-diallyltryptamine;
24        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
25        (9) Ibogaine  (some trade and other names:
26    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-

 

 

09900SB1282sam001- 29 -LRB099 03815 RLC 33711 a

1    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
2    indole; Tabernanthe iboga);
3        (10) Lysergic acid diethylamide;
4        (10.1) Salvinorin A;
5        (10.5) Salvia divinorum (meaning all parts of the plant
6    presently classified botanically as Salvia divinorum,
7    whether growing or not, the seeds thereof, any extract from
8    any part of that plant, and every compound, manufacture,
9    salts, isomers, and salts of isomers whenever the existence
10    of such salts, isomers, and salts of isomers is possible
11    within the specific chemical designation, derivative,
12    mixture, or preparation of that plant, its seeds or
13    extracts);
14        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
15        (12) Peyote (meaning all parts of the plant presently
16    classified botanically as Lophophora williamsii Lemaire,
17    whether growing or not, the seeds thereof, any extract from
18    any part of that plant, and every compound, manufacture,
19    salts, derivative, mixture, or preparation of that plant,
20    its seeds or extracts);
21        (13) N-ethyl-3-piperidyl benzilate (JB 318);
22        (14) N-methyl-3-piperidyl benzilate;
23        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
24    (also known as N-hydroxy-alpha-methyl-
25    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
26        (15) Parahexyl; some trade or other names:

 

 

09900SB1282sam001- 30 -LRB099 03815 RLC 33711 a

1    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
2    dibenzo (b,d) pyran; Synhexyl;
3        (16) Psilocybin;
4        (17) Psilocyn;
5        (18) Alpha-methyltryptamine (AMT);
6        (19) 2,5-dimethoxyamphetamine
7    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
8        (20) 4-bromo-2,5-dimethoxyamphetamine
9    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
10    4-bromo-2,5-DMA);
11        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
12    Some trade or other names: 2-(4-bromo-
13    2,5-dimethoxyphenyl)-1-aminoethane;
14    alpha-desmethyl DOB, 2CB, Nexus;
15        (21) 4-methoxyamphetamine
16    (4-methoxy-alpha-methylphenethylamine;
17    paramethoxyamphetamine; PMA);
18        (22) (Blank);
19        (23) Ethylamine analog of phencyclidine.
20    Some trade or other names:
21    N-ethyl-1-phenylcyclohexylamine,
22    (1-phenylcyclohexyl) ethylamine,
23    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
24        (24) Pyrrolidine analog of phencyclidine. Some trade
25    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
26    PHP;

 

 

09900SB1282sam001- 31 -LRB099 03815 RLC 33711 a

1        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
2        (26) 2,5-dimethoxy-4-ethylamphetamine
3    (another name: DOET);
4        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
5    (another name: TCPy);
6        (28) (Blank);
7        (29) Thiophene analog of phencyclidine (some trade
8    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
9    2-thienyl analog of phencyclidine; TPCP; TCP);
10        (30) Bufotenine (some trade or other names:
11    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
12    3-(2-dimethylaminoethyl)-5-indolol;
13    5-hydroxy-N,N-dimethyltryptamine;
14    N,N-dimethylserotonin; mappine);
15        (31)  1-Pentyl-3-(1-naphthoyl)indole 
16    Some trade or other names: JWH-018; 
17        (32) 1-Butyl-3-(1-naphthoyl)indole 
18    Some trade or other names: JWH-073;  
19        (33) 1-[(5-fluoropentyl)-1H-indol-3-yl]- 
20    (2-iodophenyl)methanone 
21    Some trade or other names: AM-694;
22        (34) 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
23    (2-methyloctan-2-yl)phenol 
24    Some trade or other names: CP 47,497 
25    and its C6, C8 and C9 homologs;
26        (34.5)  2-[(1R,3S)-3-hydroxycyclohexyl]-5- 

 

 

09900SB1282sam001- 32 -LRB099 03815 RLC 33711 a

1    (2-methyloctan-2-yl)phenol), where side chain n=5;  
2    and homologues where side chain n=4, 6, or 7;  Some  
3    trade or other names: CP 47,497; 
4        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
5    (2-methyloctan-2-yl)-6a,7, 
6    10,10a-tetrahydrobenzo[c]chromen-1-ol
7    Some trade or other names: HU-210; 
8        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
9    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
10    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
11    salts, and salts of isomers; Some trade or other  
12    names: HU-210, Dexanabinol; 
13        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
14    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
15    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
16    Some trade or other names: HU-211;
17        (37) (2-methyl-1-propyl-1H-indol-
18    3-yl)-1-naphthalenyl-methanone 
19    Some trade or other names: JWH-015;
20        (38) 4-methoxynaphthalen-1-yl-
21    (1-pentylindol-3-yl)methanone 
22    Some trade or other names: JWH-081;
23        (39) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
24    Some trade or other names: JWH-122;
25        (40) 2-(2-methylphenyl)-1-(1-pentyl-
26    1H-indol-3-yl)-ethanone 

 

 

09900SB1282sam001- 33 -LRB099 03815 RLC 33711 a

1    Some trade or other names: JWH-251;
2        (41) 1-(2-cyclohexylethyl)-3- 
3    (2-methoxyphenylacetyl)indole 
4    Some trade or other names: RCS-8, BTW-8 and SR-18; 
5        (42)  Any compound structurally derived from 
6    3-(1-naphthoyl)indole or 1H-indol-3-yl- 
7    (1-naphthyl)methane by substitution at the 
8    nitrogen atom of the indole ring by alkyl, haloalkyl, 
9    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
10    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
11    or 2-(4-morpholinyl)ethyl whether or not further 
12    substituted in the indole ring to any extent, whether 
13    or not substituted in the naphthyl ring to any extent.
14    Examples of this structural class include, but are
15    not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
16    and JWH-185;
17        (43)  Any compound structurally derived from 
18    3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
19    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
20    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
21    aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
22    or 2-(4-morpholinyl)ethyl, whether or not further 
23    substituted in the pyrrole ring to any extent, whether 
24    or not substituted in the naphthyl ring to any extent.
25    Examples of this structural class include, but are not
26    limited to, JWH-030, JWH-145, JWH-146, JWH-307, and

 

 

09900SB1282sam001- 34 -LRB099 03815 RLC 33711 a

1    JWH-368
2        (44)  Any compound structurally derived from 
3    1-(1-naphthylmethyl)indene by substitution 
4    at the 3-position of the indene ring by alkyl, haloalkyl, 
5    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
6    halide, alkyl aryl halide, 1-(N-methyl-
7    2-piperidinyl)methyl, or 2-(4-
8    morpholinyl)ethyl whether or not further substituted in
9    the indene ring to any extent, whether or not substituted
10    in the naphthyl ring to any extent. Examples of
11    this structural class include, but are not
12    limited to, JWH-176
13        (45)  Any compound structurally derived from 
14    3-phenylacetylindole by substitution at the 
15    nitrogen atom of the indole ring with alkyl, haloalkyl, 
16    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
17    halide, alkyl aryl halide, 1-(N-methyl-2-
18    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
19    whether or not further substituted in the indole ring
20    to any extent, whether or not substituted in the phenyl
21    ring to any extent. Examples of this structural
22    class include, but are not limited to, JWH-167,
23    JWH-250, JWH-251, and RCS-8
24        (46)  Any compound structurally derived from 
25    2-(3-hydroxycyclohexyl)phenol by substitution 
26    at the 5-position of the phenolic ring by alkyl, 

 

 

09900SB1282sam001- 35 -LRB099 03815 RLC 33711 a

1    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
2    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
3    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
4    whether or not substituted in the cyclohexyl ring to any
5    extent. Examples of this structural class
6    include, but are not limited to, CP 47,
7    497 and its C8 homologue (cannabicyclohexanol)
8        (46.1) Benzoylindoles: Any compound 
9    containing a 3-(benzoyl) indole structure with 
10    substitution at the nitrogen atom of the 
11    indole ring by an alkyl, haloalkyl, alkenyl, 
12    cycloalkylmethyl, cycloalkylethyl, 
13    1-(N-methyl-2-piperidinyl)methyl, 
14    or 2-(4-morpholinyl)ethyl group 
15    whether or not further substituted 
16    in the indole ring to any extent and 
17    whether or not substituted in the phenyl ring 
18    to any extent. Examples of this structural class 
19    include, but are not limited, to AM-630, 
20    AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 
21        (47)  3,4-Methylenedioxymethcathinone 
22    Some trade or other names: Methylone; 
23        (48)  3,4-Methyenedioxypyrovalerone 
24    Some trade or other names: MDPV; 
25        (49)  4-Methylmethcathinone 
26    Some trade or other names: Mephedrone; 

 

 

09900SB1282sam001- 36 -LRB099 03815 RLC 33711 a

1        (50)  4-methoxymethcathinone; 
2        (51)  4-Fluoromethcathinone; 
3        (52)  3-Fluoromethcathinone; 
4        (53)  2,5-Dimethoxy-4-(n)-propylthio- 
5    phenethylamine; 
6        (54)  5-Methoxy-N,N-diisopropyltryptamine; 
7        (55) Pentedrone;  
8        (56)  4-iodo-2,5-dimethoxy-N-((2-methoxy 
9    phenyl)methyl)-benzeneethanamine 
10    (trade or other name: 25I-NBOMe); 
11        (57) 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl) 
12    methyl]-benzeneethanamine (trade or other name: 
13    25C-NBOMe); 
14        (58)  4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl) 
15    methyl]-benzeneethanamine (trade or other name: 
16    25B-NBOMe); . 
17        (59) 3-cyclopropoylindole with 
18    substitution at the nitrogen atom of the 
19    indole ring by alkyl, haloalkyl, alkenyl, 
20    cycloalkylmethyl, cycloalkylethyl, aryl 
21    halide, alkyl aryl halide, 
22    1-(N-methyl-2-piperidinyl)methyl, or 
23    2-(4-morpholinyl)ethyl, whether or not 
24    further substituted on the indole ring 
25    to any extent, whether or not substituted 
26    on the cyclopropyl ring to any extent: 

 

 

09900SB1282sam001- 37 -LRB099 03815 RLC 33711 a

1    including but not limited to XLR11, 
2    UR144, FUB-144; 
3        (60) 3-adamantoylindole with 
4    substitution at the nitrogen atom of the 
5    indole ring by alkyl, haloalkyl, alkenyl, 
6    cycloalkylmethyl, cycloalkylethyl, 
7    aryl halide, alkyl aryl halide, 
8    1-(N-methyl-2-piperidinyl)methyl, or 
9    2-(4-morpholinyl)ethyl, whether or not 
10    further substituted on the indole ring to 
11    any extent, whether or not substituted on 
12    the adamantyl ring to any extent: including 
13    but not limited to AB-001; 
14        (61) N-(adamantyl)-indole-3-carboxamide 
15    with substitution at the nitrogen atom of the 
16    indole ring by alkyl, haloalkyl, alkenyl, 
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, 
18    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
19    or 2-(4-morpholinyl)ethyl, whether or not further 
20    substituted on the indole ring to any extent, whether 
21    or not substituted on the adamantyl ring to any 
22    extent: including but not limited to 
23    APICA/2NE-1, STS-135; 
24        (62) N-(adamantyl)-indazole-3-carboxamide 
25    with substitution at a nitrogen atom of the indazole 
26    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 

 

 

09900SB1282sam001- 38 -LRB099 03815 RLC 33711 a

1    cycloalkylethyl, aryl halide, alkyl aryl halide, 
2    1-(N-methyl-2-piperidinyl)methyl, or 
3    2-(4-morpholinyl)ethyl, whether or not further 
4    substituted on the indazole ring to any extent, 
5    whether or not substituted on the adamantyl 
6    ring to any extent: including but not limited 
7    to AKB48, 5F-AKB48; 
8        (63) 1H-indole-3-carboxylic acid 8-quinolinyl 
9    ester with substitution at the nitrogen atom of the 
10    indole ring by alkyl, haloalkyl, alkenyl, 
11    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
12    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13    2-(4-morpholinyl)ethyl, whether or not further 
14    substituted on the indole ring to any extent, 
15    whether or not substituted on the quinoline ring 
16    to any extent: including but not limited to PB22, 
17    5F-PB22, FUB-PB-22; 
18        (64) 3-(1-naphthoyl)indazole with 
19    substitution at the nitrogen atom of the 
20    indazole ring by alkyl, haloalkyl, 
21    alkenyl, cycloalkylmethyl, cycloalkylethyl, 
22    aryl halide, alkyl aryl halide, 
23    1-(N-methyl-2-piperidinyl)methyl, or 
24    2-(4-morpholinyl)ethyl, whether or not further 
25    substituted on the indazole ring to any extent, 
26    whether or not substituted on the naphthyl ring 

 

 

09900SB1282sam001- 39 -LRB099 03815 RLC 33711 a

1    to any extent: including but not limited to 
2    THJ-018, THJ-2201; 
3        (65) 2-(1-naphthoyl)benzimidazole with 
4    substitution at the nitrogen atom of the benzimidazole 
5    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
6    cycloalkylethyl, aryl halide, alkyl aryl halide, 
7    1-(N-methyl-2-piperidinyl)methyl, or 
8    2-(4-morpholinyl)ethyl, whether or not further 
9    substituted on the benzimidazole ring to any extent, 
10    whether or not substituted on the naphthyl ring to 
11    any extent: including, but not limited to FUBIMINA; 
12        (66) N-(1-amino-3-methyl-1-oxobutan-2-yl) 
13    -1H-indazole-3-carboxamide with substitution on the 
14    nitrogen atom of the indazole ring by alkyl, 
15    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
16    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
17    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
18    whether or not further substituted on the indazole 
19    ring to any extent: including but not limited to 
20    AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
21        (67) N-(1-amino-3,3-dimethyl-1-oxobutan- 
22    2-yl)-1H-indazole-3-carboxamide with substitution 
23    on the nitrogen atom of the indazole ring by alkyl, 
24    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
25    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
26    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 

 

 

09900SB1282sam001- 40 -LRB099 03815 RLC 33711 a

1    or not further substituted on the indazole ring to any 
2    extent: including but not limited to ADB-PINACA, 
3ADB-FUBINACA; 
4        (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
5    1H-indole-3-carboxamide with substitution on the nitrogen 
6    atom of the indole ring by alkyl, haloalkyl, alkenyl, 
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
8    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
9    2-(4-morpholinyl)ethyl, whether or not further 
10    substituted on the indole ring to any extent: 
11    including but not limited to ADBICA, 5F-ADBICA; 
12        (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)- 
13    1H-indole-3-carboxamide with substitution on the 
14    nitrogen atom of the indole ring by alkyl, haloalkyl, 
15    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
16    halide, alkyl aryl halide, 1-(N-methyl-2- 
17    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
18    whether or not further substituted on the indole 
19    ring to any extent: including but not limited 
20    to ABICA, 5F-ABICA; 
21        (70) Methyl 2-(1H-indazole-3-carboxamido)- 
22    3-methylbutanoate with substitution on the nitrogen 
23    atom of the indazole ring by alkyl, haloalkyl, 
24    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
25    halide, alkyl aryl halide, 1-(N-methyl-2- 
26    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 

 

 

09900SB1282sam001- 41 -LRB099 03815 RLC 33711 a

1    whether or not further substituted on the indazole 
2    ring to any extent: including but not limited to AMB, 
35F-AMB. 
4    (e) Unless specifically excepted or unless listed in
5another schedule, any material, compound, mixture, or
6preparation which contains any quantity of the following
7substances having a depressant effect on the central nervous
8system, including its salts, isomers, and salts of isomers
9whenever the existence of such salts, isomers, and salts of
10isomers is possible within the specific chemical designation:
11        (1) mecloqualone;
12        (2) methaqualone; and
13        (3) gamma hydroxybutyric acid.
14    (f) Unless specifically excepted or unless listed in
15another schedule, any material, compound, mixture, or
16preparation which contains any quantity of the following
17substances having a stimulant effect on the central nervous
18system, including its salts, isomers, and salts of isomers:
19        (1) Fenethylline;
20        (2) N-ethylamphetamine;
21        (3) Aminorex (some other names:
22    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
23    4-5-dihydro-5-phenyl-2-oxazolamine) and its
24    salts, optical isomers, and salts of optical isomers;
25        (4) Methcathinone (some other names:
26    2-methylamino-1-phenylpropan-1-one;

 

 

09900SB1282sam001- 42 -LRB099 03815 RLC 33711 a

1    Ephedrone; 2-(methylamino)-propiophenone;
2    alpha-(methylamino)propiophenone; N-methylcathinone;
3    methycathinone; Monomethylpropion; UR 1431) and its
4    salts, optical isomers, and salts of optical isomers;
5        (5) Cathinone (some trade or other names:
6    2-aminopropiophenone; alpha-aminopropiophenone;
7    2-amino-1-phenyl-propanone; norephedrone);
8        (6) N,N-dimethylamphetamine (also known as:
9    N,N-alpha-trimethyl-benzeneethanamine;
10    N,N-alpha-trimethylphenethylamine);
11        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
12    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
13        (8) 3,4-Methylenedioxypyrovalerone (MDPV).
14    (g) Temporary listing of substances subject to emergency
15scheduling. Any material, compound, mixture, or preparation
16that contains any quantity of the following substances:
17        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18    (benzylfentanyl), its optical isomers, isomers, salts,
19    and salts of isomers;
20        (2) N-[1(2-thienyl)
21   methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
22   its optical isomers, salts, and salts of isomers.
23    (h) Synthetic cathinones. Unless specifically excepted,
24any chemical compound not including bupropion, structurally
25derived from 2-aminopropan-1-one by substitution at the
261-position with either phenyl, naphthyl, or thiophene ring

 

 

09900SB1282sam001- 43 -LRB099 03815 RLC 33711 a

1systems, whether or not the compound is further modified in one
2or more of the following ways:
3        (1) by substitution in the ring system to 
4    any extent with alkyl, alkylenedioxy, alkoxy, 
5    haloalkyl, hydroxyl, or halide substituents, whether 
6    or not further substituted in the ring system 
7    by one or more other univalent substituents. 
8    Examples of this class include, but are not 
9    limited to, 3,4-Methylenedioxycathinone 
10    (bk-MDA); 
11        (2) by substitution at the 3-position 
12    with an acyclic alkyl substituent. Examples of 
13    this class include, but are not limited to, 
14    2-methylamino-1-phenylbutan-1-one 
15    (buphedrone); or 
16        (3) by substitution at the 2-amino nitrogen 
17    atom with alkyl, dialkyl, benzyl, or methoxybenzyl 
18    groups, or by inclusion of the 2-amino nitrogen atom 
19    in a cyclic structure. Examples of this class include, 
20    but are not limited to, Dimethylcathinone, Ethcathinone, 
21    and a-Pyrrolidinopropiophenone (a-PPP). 
22(Source: P.A. 97-192, eff. 7-22-11; 97-193, eff. 1-1-12;
2397-194, eff. 7-22-11; 97-334, eff. 1-1-12; 97-813, eff.
247-13-12; 97-872, eff. 7-31-12; 98-987, eff. 1-1-15.)
 
25    (720 ILCS 570/401)  (from Ch. 56 1/2, par. 1401)

 

 

09900SB1282sam001- 44 -LRB099 03815 RLC 33711 a

1    Sec. 401. Except as authorized by this Act, it is unlawful
2for any person knowingly to manufacture or deliver, or possess
3with intent to manufacture or deliver, a controlled substance
4other than methamphetamine, a counterfeit substance, or a
5controlled substance analog. A violation of this Act with
6respect to each of the controlled substances listed herein
7constitutes a single and separate violation of this Act. For
8purposes of this Section, "controlled substance analog" or
9"analog" means a substance which is intended for human
10consumption, other than a controlled substance, that has a
11chemical structure substantially similar to that of a
12controlled substance in Schedule I or II, or that was
13specifically designed to produce an effect substantially
14similar to that of a controlled substance in Schedule I or II.
15Examples of chemical classes in which controlled substance
16analogs are found include, but are not limited to, the
17following: phenethylamines, N-substituted piperidines,
18morphinans, ecgonines, quinazolinones, substituted indoles,
19and arylcycloalkylamines. For purposes of this Act, a
20controlled substance analog shall be treated in the same manner
21as the controlled substance to which it is substantially
22similar.
23    (a) Any person who violates this Section with respect to
24the following amounts of controlled or counterfeit substances
25or controlled substance analogs, notwithstanding any of the
26provisions of subsections (c), (d), (e), (f), (g) or (h) to the

 

 

09900SB1282sam001- 45 -LRB099 03815 RLC 33711 a

1contrary, is guilty of a Class X felony and shall be sentenced
2to a term of imprisonment as provided in this subsection (a)
3and fined as provided in subsection (b):
4        (1) (A) not less than 6 years and not more than 30
5        years with respect to 15 grams or more but less than
6        100 grams of a substance containing heroin, or an
7        analog thereof;
8            (B) not less than 9 years and not more than 40
9        years with respect to 100 grams or more but less than
10        400 grams of a substance containing heroin, or an
11        analog thereof;
12            (C) not less than 12 years and not more than 50
13        years with respect to 400 grams or more but less than
14        900 grams of a substance containing heroin, or an
15        analog thereof;
16            (D) not less than 15 years and not more than 60
17        years with respect to 900 grams or more of any
18        substance containing heroin, or an analog thereof;
19        (1.5) (A) not less than 6 years and not more than 30
20        years with respect to 15 grams or more but less than
21        100 grams of a substance containing fentanyl, or an
22        analog thereof;
23            (B) not less than 9 years and not more than 40
24        years with respect to 100 grams or more but less than
25        400 grams of a substance containing fentanyl, or an
26        analog thereof;

 

 

09900SB1282sam001- 46 -LRB099 03815 RLC 33711 a

1            (C) not less than 12 years and not more than 50
2        years with respect to 400 grams or more but less than
3        900 grams of a substance containing fentanyl, or an
4        analog thereof;
5            (D) not less than 15 years and not more than 60
6        years with respect to 900 grams or more of a substance
7        containing fentanyl, or an analog thereof;
8        (2) (A) not less than 6 years and not more than 30
9        years with respect to 15 grams or more but less than
10        100 grams of a substance containing cocaine, or an
11        analog thereof;
12            (B) not less than 9 years and not more than 40
13        years with respect to 100 grams or more but less than
14        400 grams of a substance containing cocaine, or an
15        analog thereof;
16            (C) not less than 12 years and not more than 50
17        years with respect to 400 grams or more but less than
18        900 grams of a substance containing cocaine, or an
19        analog thereof;
20            (D) not less than 15 years and not more than 60
21        years with respect to 900 grams or more of any
22        substance containing cocaine, or an analog thereof;
23        (3) (A) not less than 6 years and not more than 30
24        years with respect to 15 grams or more but less than
25        100 grams of a substance containing morphine, or an
26        analog thereof;

 

 

09900SB1282sam001- 47 -LRB099 03815 RLC 33711 a

1            (B) not less than 9 years and not more than 40
2        years with respect to 100 grams or more but less than
3        400 grams of a substance containing morphine, or an
4        analog thereof;
5            (C) not less than 12 years and not more than 50
6        years with respect to 400 grams or more but less than
7        900 grams of a substance containing morphine, or an
8        analog thereof;
9            (D) not less than 15 years and not more than 60
10        years with respect to 900 grams or more of a substance
11        containing morphine, or an analog thereof;
12        (4) 200 grams or more of any substance containing
13    peyote, or an analog thereof;
14        (5) 200 grams or more of any substance containing a
15    derivative of barbituric acid or any of the salts of a
16    derivative of barbituric acid, or an analog thereof;
17        (6) 200 grams or more of any substance containing
18    amphetamine or any salt of an optical isomer of
19    amphetamine, or an analog thereof;
20        (6.5) (blank);
21        (6.6) (blank);
22        (7) (A) not less than 6 years and not more than 30
23        years with respect to: (i) 15 grams or more but less
24        than 100 grams of a substance containing lysergic acid
25        diethylamide (LSD), or an analog thereof, or (ii) 15 or
26        more objects or 15 or more segregated parts of an

 

 

09900SB1282sam001- 48 -LRB099 03815 RLC 33711 a

1        object or objects but less than 200 objects or 200
2        segregated parts of an object or objects containing in
3        them or having upon them any amounts of any substance
4        containing lysergic acid diethylamide (LSD), or an
5        analog thereof;
6            (B) not less than 9 years and not more than 40
7        years with respect to: (i) 100 grams or more but less
8        than 400 grams of a substance containing lysergic acid
9        diethylamide (LSD), or an analog thereof, or (ii) 200
10        or more objects or 200 or more segregated parts of an
11        object or objects but less than 600 objects or less
12        than 600 segregated parts of an object or objects
13        containing in them or having upon them any amount of
14        any substance containing lysergic acid diethylamide
15        (LSD), or an analog thereof;
16            (C) not less than 12 years and not more than 50
17        years with respect to: (i) 400 grams or more but less
18        than 900 grams of a substance containing lysergic acid
19        diethylamide (LSD), or an analog thereof, or (ii) 600
20        or more objects or 600 or more segregated parts of an
21        object or objects but less than 1500 objects or 1500
22        segregated parts of an object or objects containing in
23        them or having upon them any amount of any substance
24        containing lysergic acid diethylamide (LSD), or an
25        analog thereof;
26            (D) not less than 15 years and not more than 60

 

 

09900SB1282sam001- 49 -LRB099 03815 RLC 33711 a

1        years with respect to: (i) 900 grams or more of any
2        substance containing lysergic acid diethylamide (LSD),
3        or an analog thereof, or (ii) 1500 or more objects or
4        1500 or more segregated parts of an object or objects
5        containing in them or having upon them any amount of a
6        substance containing lysergic acid diethylamide (LSD),
7        or an analog thereof;
8        (7.5) (A) not less than 6 years and not more than 30
9        years with respect to: (i) 15 grams or more but less
10        than 100 grams of a substance listed in paragraph (1),
11        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12        (21), (25), or (26) of subsection (d) of Section 204,
13        or an analog or derivative thereof, or (ii) 15 or more
14        pills, tablets, caplets, capsules, or objects but less
15        than 200 pills, tablets, caplets, capsules, or objects
16        containing in them or having upon them any amounts of
17        any substance listed in paragraph (1), (2), (2.1),
18        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
19        (26) of subsection (d) of Section 204, or an analog or
20        derivative thereof;
21            (B) not less than 9 years and not more than 40
22        years with respect to: (i) 100 grams or more but less
23        than 400 grams of a substance listed in paragraph (1),
24        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
25        (21), (25), or (26) of subsection (d) of Section 204,
26        or an analog or derivative thereof, or (ii) 200 or more

 

 

09900SB1282sam001- 50 -LRB099 03815 RLC 33711 a

1        pills, tablets, caplets, capsules, or objects but less
2        than 600 pills, tablets, caplets, capsules, or objects
3        containing in them or having upon them any amount of
4        any substance listed in paragraph (1), (2), (2.1),
5        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
6        (26) of subsection (d) of Section 204, or an analog or
7        derivative thereof;
8            (C) not less than 12 years and not more than 50
9        years with respect to: (i) 400 grams or more but less
10        than 900 grams of a substance listed in paragraph (1),
11        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12        (21), (25), or (26) of subsection (d) of Section 204,
13        or an analog or derivative thereof, or (ii) 600 or more
14        pills, tablets, caplets, capsules, or objects but less
15        than 1,500 pills, tablets, caplets, capsules, or
16        objects containing in them or having upon them any
17        amount of any substance listed in paragraph (1), (2),
18        (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
19        (25), or (26) of subsection (d) of Section 204, or an
20        analog or derivative thereof;
21            (D) not less than 15 years and not more than 60
22        years with respect to: (i) 900 grams or more of any
23        substance listed in paragraph (1), (2), (2.1), (2.2),
24        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
25        subsection (d) of Section 204, or an analog or
26        derivative thereof, or (ii) 1,500 or more pills,

 

 

09900SB1282sam001- 51 -LRB099 03815 RLC 33711 a

1        tablets, caplets, capsules, or objects containing in
2        them or having upon them any amount of a substance
3        listed in paragraph (1), (2), (2.1), (2.2), (3),
4        (14.1), (19), (20), (20.1), (21), (25), or (26) of
5        subsection (d) of Section 204, or an analog or
6        derivative thereof;
7        (8) 30 grams or more of any substance containing
8    pentazocine or any of the salts, isomers and salts of
9    isomers of pentazocine, or an analog thereof;
10        (9) 30 grams or more of any substance containing
11    methaqualone or any of the salts, isomers and salts of
12    isomers of methaqualone, or an analog thereof;
13        (10) 30 grams or more of any substance containing
14    phencyclidine or any of the salts, isomers and salts of
15    isomers of phencyclidine (PCP), or an analog thereof;
16        (10.5) 30 grams or more of any substance containing
17    ketamine or any of the salts, isomers and salts of isomers
18    of ketamine, or an analog thereof;
19        (10.6) 100 grams or more of any substance containing
20    hydrocodone, or any of the salts, isomers and salts of
21    isomers of hydrocodone, or an analog thereof;
22        (10.7) 100 grams or more of any substance containing
23    dihydrocodeinone, or any of the salts, isomers and salts of
24    isomers of dihydrocodeinone, or an analog thereof;
25        (10.8) 100 grams or more of any substance containing
26    dihydrocodeine, or any of the salts, isomers and salts of

 

 

09900SB1282sam001- 52 -LRB099 03815 RLC 33711 a

1    isomers of dihydrocodeine, or an analog thereof;
2        (10.9) 100 grams or more of any substance containing
3    oxycodone, or any of the salts, isomers and salts of
4    isomers of oxycodone, or an analog thereof;
5        (11) 200 grams or more of any substance containing any
6    other controlled substance classified in Schedules I or II,
7    or an analog thereof, which is not otherwise included in
8    this subsection.
9    (b) Any person sentenced with respect to violations of
10paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
11involving 100 grams or more of the controlled substance named
12therein, may in addition to the penalties provided therein, be
13fined an amount not more than $500,000 or the full street value
14of the controlled or counterfeit substance or controlled
15substance analog, whichever is greater. The term "street value"
16shall have the meaning ascribed in Section 110-5 of the Code of
17Criminal Procedure of 1963. Any person sentenced with respect
18to any other provision of subsection (a), may in addition to
19the penalties provided therein, be fined an amount not to
20exceed $500,000.
21    (b-1) Excluding violations of this Act when the controlled
22substance is fentanyl, any person sentenced to a term of
23imprisonment with respect to violations of Section 401, 401.1,
24405, 405.1, 405.2, or 407, when the substance containing the
25controlled substance contains any amount of fentanyl, 3 years
26shall be added to the term of imprisonment imposed by the

 

 

09900SB1282sam001- 53 -LRB099 03815 RLC 33711 a

1court, and the maximum sentence for the offense shall be
2increased by 3 years.
3    (c) Any person who violates this Section with regard to the
4following amounts of controlled or counterfeit substances or
5controlled substance analogs, notwithstanding any of the
6provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
7to the contrary, is guilty of a Class 1 felony. The fine for
8violation of this subsection (c) shall not be more than
9$250,000:
10        (1) 1 gram or more but less than 15 grams of any
11    substance containing heroin, or an analog thereof;
12        (1.5) 1 gram or more but less than 15 grams of any
13    substance containing fentanyl, or an analog thereof;
14        (2) 1 gram or more but less than 15 grams of any
15    substance containing cocaine, or an analog thereof;
16        (3) 10 grams or more but less than 15 grams of any
17    substance containing morphine, or an analog thereof;
18        (4) 50 grams or more but less than 200 grams of any
19    substance containing peyote, or an analog thereof;
20        (5) 50 grams or more but less than 200 grams of any
21    substance containing a derivative of barbituric acid or any
22    of the salts of a derivative of barbituric acid, or an
23    analog thereof;
24        (6) 50 grams or more but less than 200 grams of any
25    substance containing amphetamine or any salt of an optical
26    isomer of amphetamine, or an analog thereof;

 

 

09900SB1282sam001- 54 -LRB099 03815 RLC 33711 a

1        (6.5) (blank);
2        (7) (i) 5 grams or more but less than 15 grams of any
3    substance containing lysergic acid diethylamide (LSD), or
4    an analog thereof, or (ii) more than 10 objects or more
5    than 10 segregated parts of an object or objects but less
6    than 15 objects or less than 15 segregated parts of an
7    object containing in them or having upon them any amount of
8    any substance containing lysergic acid diethylamide (LSD),
9    or an analog thereof;
10        (7.5) (i) 5 grams or more but less than 15 grams of any
11    substance listed in paragraph (1), (2), (2.1), (2.2), (3),
12    (14.1), (19), (20), (20.1), (21), (25), or (26) of
13    subsection (d) of Section 204, or an analog or derivative
14    thereof, or (ii) more than 10 pills, tablets, caplets,
15    capsules, or objects but less than 15 pills, tablets,
16    caplets, capsules, or objects containing in them or having
17    upon them any amount of any substance listed in paragraph
18    (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
19    (21), (25), or (26) of subsection (d) of Section 204, or an
20    analog or derivative thereof;
21        (8) 10 grams or more but less than 30 grams of any
22    substance containing pentazocine or any of the salts,
23    isomers and salts of isomers of pentazocine, or an analog
24    thereof;
25        (9) 10 grams or more but less than 30 grams of any
26    substance containing methaqualone or any of the salts,

 

 

09900SB1282sam001- 55 -LRB099 03815 RLC 33711 a

1    isomers and salts of isomers of methaqualone, or an analog
2    thereof;
3        (10) 10 grams or more but less than 30 grams of any
4    substance containing phencyclidine or any of the salts,
5    isomers and salts of isomers of phencyclidine (PCP), or an
6    analog thereof;
7        (10.5) 10 grams or more but less than 30 grams of any
8    substance containing ketamine or any of the salts, isomers
9    and salts of isomers of ketamine, or an analog thereof;
10        (10.6) 50 grams or more but less than 100 grams of any
11    substance containing hydrocodone, or any of the salts,
12    isomers and salts of isomers of hydrocodone, or an analog
13    thereof;
14        (10.7) 50 grams or more but less than 100 grams of any
15    substance containing dihydrocodeinone, or any of the
16    salts, isomers and salts of isomers of dihydrocodeinone, or
17    an analog thereof;
18        (10.8) 50 grams or more but less than 100 grams of any
19    substance containing dihydrocodeine, or any of the salts,
20    isomers and salts of isomers of dihydrocodeine, or an
21    analog thereof;
22        (10.9) 50 grams or more but less than 100 grams of any
23    substance containing oxycodone, or any of the salts,
24    isomers and salts of isomers of oxycodone, or an analog
25    thereof;
26        (11) 50 grams or more but less than 200 grams of any

 

 

09900SB1282sam001- 56 -LRB099 03815 RLC 33711 a

1    substance containing a substance classified in Schedules I
2    or II, or an analog thereof, which is not otherwise
3    included in this subsection.
4    (c-5) (Blank).
5    (d) Any person who violates this Section with regard to any
6other amount of a controlled or counterfeit substance
7containing dihydrocodeinone or dihydrocodeine or classified in
8Schedules I or II, or an analog thereof, which is (i) a
9narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
10analog thereof, (iii) any substance containing amphetamine or
11fentanyl or any salt or optical isomer of amphetamine or
12fentanyl, or an analog thereof, or (iv) any substance
13containing N-Benzylpiperazine (BZP) or any salt or optical
14isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
15guilty of a Class 2 felony. The fine for violation of this
16subsection (d) shall not be more than $200,000.
17    (d-5) (Blank).
18    (e) Any person who violates this Section with regard to any
19other amount of a controlled substance other than
20methamphetamine or counterfeit substance classified in
21Schedule I or II, or an analog thereof, which substance is not
22included under subsection (d) of this Section, is guilty of a
23Class 3 felony. The fine for violation of this subsection (e)
24shall not be more than $150,000.
25    (f) Any person who violates this Section with regard to any
26other amount of a controlled or counterfeit substance

 

 

09900SB1282sam001- 57 -LRB099 03815 RLC 33711 a

1classified in Schedule III is guilty of a Class 3 felony. The
2fine for violation of this subsection (f) shall not be more
3than $125,000.
4    (g) Any person who violates this Section with regard to any
5other amount of a controlled or counterfeit substance
6classified in Schedule IV is guilty of a Class 3 felony. The
7fine for violation of this subsection (g) shall not be more
8than $100,000.
9    (h) Any person who violates this Section with regard to any
10other amount of a controlled or counterfeit substance
11classified in Schedule V is guilty of a Class 3 felony. The
12fine for violation of this subsection (h) shall not be more
13than $75,000.
14    (i) This Section does not apply to the manufacture,
15possession or distribution of a substance in conformance with
16the provisions of an approved new drug application or an
17exemption for investigational use within the meaning of Section
18505 of the Federal Food, Drug and Cosmetic Act.
19    (j) (Blank).
20(Source: P.A. 96-347, eff. 1-1-10; 97-997, eff. 1-1-13.)
 
21    (720 ILCS 570/402)  (from Ch. 56 1/2, par. 1402)
22    Sec. 402. Except as otherwise authorized by this Act, it is
23unlawful for any person knowingly to possess a controlled or
24counterfeit substance or controlled substance analog. A
25violation of this Act with respect to each of the controlled

 

 

09900SB1282sam001- 58 -LRB099 03815 RLC 33711 a

1substances listed herein constitutes a single and separate
2violation of this Act. For purposes of this Section,
3"controlled substance analog" or "analog" means a substance
4which is intended for human consumption, other than a
5controlled substance, that has a chemical structure
6substantially similar to that of a controlled substance in
7Schedule I or II, or that was specifically designed to produce
8an effect substantially similar to that of a controlled
9substance in Schedule I or II. Examples of chemical classes in
10which controlled substance analogs are found include, but are
11not limited to, the following: phenethylamines, N-substituted
12piperidines, morphinans, ecgonines, quinazolinones,
13substituted indoles, and arylcycloalkylamines. For purposes of
14this Act, a controlled substance analog shall be treated in the
15same manner as the controlled substance to which it is
16substantially similar.
17    (a) Any person who violates this Section with respect to
18the following controlled or counterfeit substances and
19amounts, notwithstanding any of the provisions of subsections
20(c) and (d) to the contrary, is guilty of a Class 1 felony and
21shall, if sentenced to a term of imprisonment, be sentenced as
22provided in this subsection (a) and fined as provided in
23subsection (b):
24        (1) (A) not less than 4 years and not more than 15
25        years with respect to 15 grams or more but less than
26        100 grams of a substance containing heroin;

 

 

09900SB1282sam001- 59 -LRB099 03815 RLC 33711 a

1            (B) not less than 6 years and not more than 30
2        years with respect to 100 grams or more but less than
3        400 grams of a substance containing heroin;
4            (C) not less than 8 years and not more than 40
5        years with respect to 400 grams or more but less than
6        900 grams of any substance containing heroin;
7            (D) not less than 10 years and not more than 50
8        years with respect to 900 grams or more of any
9        substance containing heroin;
10        (2) (A) not less than 4 years and not more than 15
11        years with respect to 15 grams or more but less than
12        100 grams of any substance containing cocaine;
13            (B) not less than 6 years and not more than 30
14        years with respect to 100 grams or more but less than
15        400 grams of any substance containing cocaine;
16            (C) not less than 8 years and not more than 40
17        years with respect to 400 grams or more but less than
18        900 grams of any substance containing cocaine;
19            (D) not less than 10 years and not more than 50
20        years with respect to 900 grams or more of any
21        substance containing cocaine;
22        (3) (A) not less than 4 years and not more than 15
23        years with respect to 15 grams or more but less than
24        100 grams of any substance containing morphine;
25            (B) not less than 6 years and not more than 30
26        years with respect to 100 grams or more but less than

 

 

09900SB1282sam001- 60 -LRB099 03815 RLC 33711 a

1        400 grams of any substance containing morphine;
2            (C) not less than 6 years and not more than 40
3        years with respect to 400 grams or more but less than
4        900 grams of any substance containing morphine;
5            (D) not less than 10 years and not more than 50
6        years with respect to 900 grams or more of any
7        substance containing morphine;
8        (4) 200 grams or more of any substance containing
9    peyote;
10        (5) 200 grams or more of any substance containing a
11    derivative of barbituric acid or any of the salts of a
12    derivative of barbituric acid;
13        (6) 200 grams or more of any substance containing
14    amphetamine or any salt of an optical isomer of
15    amphetamine;
16        (6.5) (blank);
17        (7) (A) not less than 4 years and not more than 15
18        years with respect to: (i) 15 grams or more but less
19        than 100 grams of any substance containing lysergic
20        acid diethylamide (LSD), or an analog thereof, or (ii)
21        15 or more objects or 15 or more segregated parts of an
22        object or objects but less than 200 objects or 200
23        segregated parts of an object or objects containing in
24        them or having upon them any amount of any substance
25        containing lysergic acid diethylamide (LSD), or an
26        analog thereof;

 

 

09900SB1282sam001- 61 -LRB099 03815 RLC 33711 a

1            (B) not less than 6 years and not more than 30
2        years with respect to: (i) 100 grams or more but less
3        than 400 grams of any substance containing lysergic
4        acid diethylamide (LSD), or an analog thereof, or (ii)
5        200 or more objects or 200 or more segregated parts of
6        an object or objects but less than 600 objects or less
7        than 600 segregated parts of an object or objects
8        containing in them or having upon them any amount of
9        any substance containing lysergic acid diethylamide
10        (LSD), or an analog thereof;
11            (C) not less than 8 years and not more than 40
12        years with respect to: (i) 400 grams or more but less
13        than 900 grams of any substance containing lysergic
14        acid diethylamide (LSD), or an analog thereof, or (ii)
15        600 or more objects or 600 or more segregated parts of
16        an object or objects but less than 1500 objects or 1500
17        segregated parts of an object or objects containing in
18        them or having upon them any amount of any substance
19        containing lysergic acid diethylamide (LSD), or an
20        analog thereof;
21            (D) not less than 10 years and not more than 50
22        years with respect to: (i) 900 grams or more of any
23        substance containing lysergic acid diethylamide (LSD),
24        or an analog thereof, or (ii) 1500 or more objects or
25        1500 or more segregated parts of an object or objects
26        containing in them or having upon them any amount of a

 

 

09900SB1282sam001- 62 -LRB099 03815 RLC 33711 a

1        substance containing lysergic acid diethylamide (LSD),
2        or an analog thereof;
3        (7.5) (A) not less than 4 years and not more than 15
4        years with respect to: (i) 15 grams or more but less
5        than 100 grams of any substance listed in paragraph
6        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7        (20.1), (21), (25), or (26) of subsection (d) of
8        Section 204, or an analog or derivative thereof, or
9        (ii) 15 or more pills, tablets, caplets, capsules, or
10        objects but less than 200 pills, tablets, caplets,
11        capsules, or objects containing in them or having upon
12        them any amount of any substance listed in paragraph
13        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
14        (20.1), (21), (25), or (26) of subsection (d) of
15        Section 204, or an analog or derivative thereof;
16            (B) not less than 6 years and not more than 30
17        years with respect to: (i) 100 grams or more but less
18        than 400 grams of any substance listed in paragraph
19        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
20        (20.1), (21), (25), or (26) of subsection (d) of
21        Section 204, or an analog or derivative thereof, or
22        (ii) 200 or more pills, tablets, caplets, capsules, or
23        objects but less than 600 pills, tablets, caplets,
24        capsules, or objects containing in them or having upon
25        them any amount of any substance listed in paragraph
26        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),

 

 

09900SB1282sam001- 63 -LRB099 03815 RLC 33711 a

1        (20.1), (21), (25), or (26) of subsection (d) of
2        Section 204, or an analog or derivative thereof;
3            (C) not less than 8 years and not more than 40
4        years with respect to: (i) 400 grams or more but less
5        than 900 grams of any substance listed in paragraph
6        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7        (20.1), (21), (25), or (26) of subsection (d) of
8        Section 204, or an analog or derivative thereof, or
9        (ii) 600 or more pills, tablets, caplets, capsules, or
10        objects but less than 1,500 pills, tablets, caplets,
11        capsules, or objects containing in them or having upon
12        them any amount of any substance listed in paragraph
13        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
14        (20.1), (21), (25), or (26) of subsection (d) of
15        Section 204, or an analog or derivative thereof;
16            (D) not less than 10 years and not more than 50
17        years with respect to: (i) 900 grams or more of any
18        substance listed in paragraph (1), (2), (2.1), (2.2),
19        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
20        subsection (d) of Section 204, or an analog or
21        derivative thereof, or (ii) 1,500 or more pills,
22        tablets, caplets, capsules, or objects containing in
23        them or having upon them any amount of a substance
24        listed in paragraph (1), (2), (2.1), (2.2), (3),
25        (14.1), (19), (20), (20.1), (21), (25), or (26) of
26        subsection (d) of Section 204, or an analog or

 

 

09900SB1282sam001- 64 -LRB099 03815 RLC 33711 a

1        derivative thereof;
2        (8) 30 grams or more of any substance containing
3    pentazocine or any of the salts, isomers and salts of
4    isomers of pentazocine, or an analog thereof;
5        (9) 30 grams or more of any substance containing
6    methaqualone or any of the salts, isomers and salts of
7    isomers of methaqualone;
8        (10) 30 grams or more of any substance containing
9    phencyclidine or any of the salts, isomers and salts of
10    isomers of phencyclidine (PCP);
11        (10.5) 30 grams or more of any substance containing
12    ketamine or any of the salts, isomers and salts of isomers
13    of ketamine;
14        (11) 200 grams or more of any substance containing any
15    substance classified as a narcotic drug in Schedules I or
16    II, or an analog thereof, which is not otherwise included
17    in this subsection.
18    (b) Any person sentenced with respect to violations of
19paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
20involving 100 grams or more of the controlled substance named
21therein, may in addition to the penalties provided therein, be
22fined an amount not to exceed $200,000 or the full street value
23of the controlled or counterfeit substances, whichever is
24greater. The term "street value" shall have the meaning
25ascribed in Section 110-5 of the Code of Criminal Procedure of
261963. Any person sentenced with respect to any other provision

 

 

09900SB1282sam001- 65 -LRB099 03815 RLC 33711 a

1of subsection (a), may in addition to the penalties provided
2therein, be fined an amount not to exceed $200,000.
3    (c) Any person who violates this Section with regard to an
4amount of a controlled substance other than methamphetamine or
5counterfeit substance not set forth in subsection (a) or (d) is
6guilty of a Class 4 felony. The fine for a violation punishable
7under this subsection (c) shall not be more than $25,000.
8    (d) Any person who violates this Section with regard to any
9amount of anabolic steroid is guilty of a Class C misdemeanor
10for the first offense and a Class B misdemeanor for a
11subsequent offense committed within 2 years of a prior
12conviction.
13(Source: P.A. 95-331, eff. 8-21-07; 96-347, eff. 1-1-10.)".